Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-18
2011-12-27
Westerberg, Nissa (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08084461
ABSTRACT:
The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide in a 0.5 ml volume.
REFERENCES:
patent: 6247617 (2001-06-01), Clyde et al.
patent: 6679249 (2004-01-01), Addington et al.
patent: WO 94/13263 (1994-06-01), None
Asmus, M.A.; Sherman, J.; Hendeles, L.; “Bronchoconstrictor additives in bronchodilator solutions”, J Allergy Clin Immunol, 104(2), p. S53-S60, 1999.
Campbell, S.; “For COPD a Combination of Ipratropium Bromide and Albuterol Sulfate is More Effective than Albuterol Base”, Arch Intern Med, 159, p. 156-160, 1999.
Remington: The Science and Practice of Pharmacy, Nineteenth Edition, 1995, vol. 1, p. 806.
Coates, AL and Ho, SL, “Drug Adminsitration by Jet Nebulization”, Pediatirc Pulmonology, 26, p. 412-423, 1998.
Tandon et al. “Measuring Nebulizer Output: aerosol Production vs Gravimetric Analysis”, Chest 111, p. 1361-65, 1997.
Combivent(R) Data Sheet, Prepared Mar. 25, 1999.
The Combivnent Inhalation Solution Study Group, Chest, 112, p. 1514-15231, 1997.
The Merck Index, 10th edition, Merck & Co., Inc.: Rahway, JN 1983, pp. 10, entry 58.
The NIST Reference on Constants, Units, and Uncertainty: International System of Units (SI), SI prefixes, accessed on Dec. 10, 2010 at physics.nist.gov/Units/prefixes.html.
Office Action from related U.S. Appl. No. 11/541,523, mailed Dec. 21, 2010.
Gross, N., et al.:“Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease” Respiration, Karger, Basel, CH LNKD D01:10.1159/000029295, vol. 65, No. 5, Sep. 1, 1998, pp. 354-362, XP008103328 ISSN: 0025-7931; p. 355, col. 1, line 1; p. 357, col. 2, paragraph 2.
European Search Report for European Application No. 02789216.5, dated Jun. 18 2010.
Faruk, A. et al.,Effect of Drug Concentration and Permeation Enhancer on Iontophoretic Transport of Salbutamol Sulphatein vitro, Research Paper, International Journal of Pharmaceutical Sciences and Nanotechnology, vol. 1, Issue 4, Jan.-Mar. 2009, pp. 341-348.
Hakes, L. B. et al.,The Stability of Salbutamol Solution, J. Pharm. Pharmacol., vol. 31 (Suppl.), (1979), p. 25P.
Hindle, M. et al.,Determination of the Relative Bioavailability of Salbutamol to the Lung Following Inhalation, Br. J. Clin. Pharmac., vol. 34, (1992), pp. 311-315.
Lipworth, B. J.,Pharmacokinetics of Inhaled Drugs, Br J Clin Pharmacol, vol. 42 (1996), pp. 697-705.
Malkki, L. et al.,Decomposition of Salbutamol in Aqueous Solutions. I. The Effect of pH, Temperature and Drug Concentration, International Journal of Pharmaceutics, vol. 63, (1990), pp. 17-22.
Rosethorne, E. M. et al.,Efficacy is a Contributing Factor to the Clinical Onset of Broncodilation of Inhaled β2-adrenoceptor Agonists, Naunyn-Schmied Arch Pharmacol, 382, (2010), pp. 255-263.
Silkstone, V. L. et al.,Determination of the Relative Bioavailability of Salbutamol to the Lungs and Systemic Circulation Following Nebulization, Br J Clin Pharmacol, vol. 54, (2002), pp. 115-119.
Walker, S. R. et al.,The Clinical Pharmacology of Oral and Inhaled Salbutamol, Clinical Pharmacology and Therapeutics, vol. 13, No. 6, (1972), pp. 861-867.
DuoNeb™ Inhalation Solution (proposed package insert), NDA 20-950, Center for Drug Evaluation and Research, Dey L.P., Mar. 16, 2001, 25 pages.
R-Albuterol, Preclinical and Clinical Pharmacology of R-Albuterol, From Molecule to Man, Clinical Reviews in Allergy and Immunology, vol. 14, (1996) pp. 1-2.
Improved stability in oral delivery of albuterol p . . . [Ann Allergy. 1991]—66(4), p. 324-7, PubMed result [online] [retrieved Oct. 10, 2010]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/pubmed/2014933>. 1 page, Abstract only.
Banerjee Partha
Chaudry Imtiaz
Alston & Bird LLP
Dey L.P.
Westerberg Nissa
LandOfFree
Albuterol and ipratropium inhalation solution, system, kit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Albuterol and ipratropium inhalation solution, system, kit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Albuterol and ipratropium inhalation solution, system, kit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260026